With a headquarter in Helsinki, Finland, Affix Labs has years of success with their other products focusing on fighting against insect-borne diseases such as Malaria, Dengue and Zika viruses. Their proprietary technology focuses on binding safe chemicals in a way that boosts their effectiveness and longevity.AFFIX Labs
Affix Labs Oy
P.O. Box 176
+358 9 8561 7167
3 Aug 2020
Leading chemical binding expert AFFIX Labs has harnessed its global experience in disease prevention to create the first long-lasting surface treatment proven to kill the coronavirus (COVID-19). Now available in Europe and the UAE and launching in new global markets, the surface treatment, known as Si-Quat, combines a safe and well-established disinfectant with the lab’s proprietary chemical binding technique.
20 Jul 2020
Leading chemical binding expert AFFIX Labs has harnessed its global experience in disease prevention to create the first long-lasting surface treatment proven to kill COVID-19. Si-Quat combines a safe and well-established disinfectant and a proprietary chemical binding technique, so that the active ingredient can kill viruses, including SARS-COV-2. Testing at Portugal’s Biochemistry Institute at the University of Lisbon proves that Si-Quat effectively kills the COVID-19 pathogens that it comes into contact with.